Bioton

Bioton expands insulin access in more countries through technology development, education, and scientific support for local communities.

Bioton integrates ESG principles—environmental care, societal impact, and transparent governance—into its strategy.

Bioton develops and improves production technologies to meet current patient and diabetic market needs.

Bioton’s facility in Macierzysze near Warsaw is one of the world’s most advanced biotech plants, where insulin is produced.

Bioton is a Polish biotech company offering patients safe, comprehensive diabetes treatment solutions.

BIOTON highlights how technology addresses diabetes, a growing global health challenge driven by lifestyle factors like stress, diet, and physical inactivity. The company emphasizes the role of modern solutions in managing blood glucose levels amid rising prevalence. BIOTON’s focus aligns technology with practical, real-world applications for diabetes care.

Nov 2025bioton.comNews article

BIOTON operates as Europe’s sole domestic manufacturer producing insulin end-to-end—from active substance biosynthesis to finished product—over a 25-year span. The company addresses critical drug shortages by mitigating supply chain disruptions and corporate withdrawals from human insulin markets. Its integrated production model positions BIOTON to meet regional demand in Poland and beyond.

Sep 2025bioton.comNews article

Polish biotech firm **Bioton S.A.** hosted EU ministers and European Commission delegates in a study visit on February 3, 2025. The meeting, organized by Poland’s Ministry of Development and Technology, preceded an EU-wide session on industry, trade, and internal market policies. Bioton, listed on the Warsaw Stock Exchange (GPW), engaged with officials to discuss biotechnology advancements and their role in the European economy.

Mar 2025bioton.comNews article

Jeremy Launders discusses the future of biopharma innovation and patient access challenges in an interview with *Euro Health Leaders*. The conversation explores evolving industry trends and strategies to improve therapy accessibility. Launders addresses key questions on biopharma development and operational values.

Feb 2025bioton.comNews article